215 related articles for article (PubMed ID: 25389781)
1. FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.
Gromov P; Espinoza JA; Talman ML; Honma N; Kroman N; Timmermans Wielenga V; Moreira JM; Gromova I
PLoS One; 2014; 9(11):e112024. PubMed ID: 25389781
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.
Celis JE; Cabezón T; Moreira JM; Gromov P; Gromova I; Timmermans-Wielenga V; Iwase T; Akiyama F; Honma N; Rank F
Mol Oncol; 2009 Jun; 3(3):220-37. PubMed ID: 19393583
[TBL] [Abstract][Full Text] [Related]
3. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
4. 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.
Celis JE; Gromov P; Cabezón T; Moreira JM; Friis E; Jirström K; Llombart-Bosch A; Timmermans-Wielenga V; Rank F; Gromova I
Mol Cell Proteomics; 2008 Oct; 7(10):1795-809. PubMed ID: 18632593
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
Celis JE; Gromova I; Gromov P; Moreira JM; Cabezón T; Friis E; Rank F
FEBS Lett; 2006 May; 580(12):2935-44. PubMed ID: 16631754
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer.
Alshareeda AT; Rakha EA; Nolan CC; Ellis IO; Green AR
Breast Cancer Res Treat; 2012 Jul; 134(2):519-29. PubMed ID: 22562177
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
9. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
[TBL] [Abstract][Full Text] [Related]
10. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
Vranic S; Gurjeva O; Frkovic-Grazio S; Palazzo J; Tawfik O; Gatalica Z
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
[TBL] [Abstract][Full Text] [Related]
11. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
12. Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
Celis JE; Moreira JM; Gromova I; Cabezón T; Gromov P; Shen T; Timmermans V; Rank F
Mol Oncol; 2007 Jun; 1(1):97-119. PubMed ID: 19383289
[TBL] [Abstract][Full Text] [Related]
13. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
D'Arcy C; Quinn CM
J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
[TBL] [Abstract][Full Text] [Related]
14. α-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation.
Nakamura H; Kukita Y; Kunimasa K; Kittaka N; Kusama H; Nakayama T; Tamaki Y; Sugiura R; Yasuda H; Hashimoto M; Yamamoto T; Imamura F; Nakatsuka SI
Hum Pathol; 2021 Oct; 116():39-48. PubMed ID: 34314764
[TBL] [Abstract][Full Text] [Related]
15. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation.
Wang J; Peng Y; Sun H; Aung PP; Resetkova E; Yam C; Sahin AA; Huo L; Ding Q
Arch Pathol Lab Med; 2024 Feb; 148(2):200-205. PubMed ID: 37074839
[TBL] [Abstract][Full Text] [Related]
16. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M
Breast Cancer Res; 2012 Jul; 14(4):R111. PubMed ID: 22817771
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
Choi J; Jung WH; Koo JS
Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
[TBL] [Abstract][Full Text] [Related]
18. ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast.
Vranic S; Gatalica Z; Deng H; Frkovic-Grazio S; Lee LM; Gurjeva O; Wang ZY
J Clin Pathol; 2011 Jan; 64(1):54-7. PubMed ID: 21045236
[TBL] [Abstract][Full Text] [Related]
19. A fatty acid-binding protein 7/RXRβ pathway enhances survival and proliferation in triple-negative breast cancer.
Liu RZ; Graham K; Glubrecht DD; Lai R; Mackey JR; Godbout R
J Pathol; 2012 Nov; 228(3):310-21. PubMed ID: 22322885
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma.
Bhargava R; Beriwal S; McManus K; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):218-25. PubMed ID: 21217522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]